Galena Biopharma (GALE) Misses Q2 EPS by 8c

Galena Biopharma (NASDAQ: GALE) reported Q2 EPS of ($0.17), $0.08 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $2.3 million versus the consensus estimate of $2.99 million.

For earnings history and earnings-related data on Galena Biopharma (GALE) click here.

You May Also Be Interested In

• Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
• First Cash Financial (FCFS) PT Lowered to $140 at TD Cowen
• First BanCorp (FBP) PT Raised to $21 at Keefe, Bruyette & Woods